VEGFA and breast carcinoma: VEGF-A targeted NIR-imaging using bevacuzimab-IRDye800CW, a monoclonal anti-VEGF antibody conjugated to IRDye800CW (800 nm), has been described in patients with breast cancer as well as with colorectal peritoneal metastases.